PDF(Pubmed)
Abstract：
Monkeypox is a zoonotic viral disease. Monkeypox was first reported in humans about 54 years ago. Prior to the global outbreak, monkeypox was endemic to the rainforests of central and western African countries. In the last three years, increasing numbers of human monkeypox have been reported from various countries. Responding to the severity, monkeypox was declared a Public Health Emergency of International Concern by the World Health Organization. In the absence of approved drugs or clinical studies, repurposed drugs and therapeutic medical countermeasures effective against other orthopoxviruses have been utilized to treat severe human monkeypox cases. Currently, clinical trials are underway exploring the potential therapeutic effectiveness of tecovirimate in human monkeypox cases. Monoclonal antibodies, IFN-β, resveratrol, and 15 triple-targeting FDA-approved drugs represent potential new drug targets for human monkeypox, necessitating further research.
摘要：
猴痘是一种人畜共患病毒性疾病。大约54年前，猴痘首次在人类中被报道。在全球爆发之前，猴痘是中部和西部非洲国家热带雨林特有的。在过去的三年里,据报道，不同国家的猴痘数量越来越多。根据严重性，猴痘被世界卫生组织宣布为国际关注的突发公共卫生事件。在没有批准的药物或临床研究的情况下，对其他正痘病毒有效的再利用药物和治疗医学对策已被用于治疗严重的人类猴痘病例。目前,临床试验正在进行中，探索tecovirimate在人类猴痘病例中的潜在治疗效果。单克隆抗体,IFN-β,白藜芦醇,FDA批准的15种三重靶向药物代表了人类猴痘的潜在新药靶标，需要进一步研究。
